Pulmonary Fibrosis News Home | Pulmonary Fibrosis News
2024年12月10日 · Blocking HIF2 protein may promote lung repair in IPF: Mouse study. Inhibiting the HIF2 protein — fully, hypoxia-inducible factor 2 — was found to ease scarring in a mouse model of lung injury and could be a promising therapeutic strategy for treating idiopathic pulmonary fibrosis (IPF), according to the results of new preclinical research.
New prototype therapy may repair IPF lung scarring by …
2024年4月26日 · The study provides pharmacological proof of concept for an upcoming Phase 1 clinical trial that’s evaluating CMR316, an investigational inhalable therapy similar to the designed prototype. “Most drugs act by slowing the progression of disease; our approach is to make drugs that control cell fate to stop or reverse the disease process,” Peter G. Schultz, PhD, president and CEO of Scripps ...
Pulmonary Fibrosis Symptoms, Diagnosis, Prognosis and Treatment
Recent Posts. Keeping new year’s resolutions that affect pulmonary fibrosis January 7, 2025; Enzyme responsible for fatty acid may be IPF therapeutic target January 3, 2025; Trial: LYT-100 better than Esbriet in slowing lung function decline in IPF December 20, 2024; Ways to handle the isolation that can come with the holidays December 17, …
12 Facts About Pulmonary Fibrosis Prognosis and Life Expectancy
2019年8月16日 · To address some misconceptions about the prognosis of pulmonary fibrosis and life expectancy of patients, we’ve put together some frequently asked questions (and answers) to help:<. What causes pulmonary fibrosis? Some cases of pulmonary fibrosis occur without known cause (this is called idiopathic pulmonary fibrosis).Other cases are caused by exposure to environmental hazards (such as ...
BMS-986278 declared breakthrough therapy for progressive PF
2023年10月27日 · Breakthrough therapy designation is intended to expedite the development and review of medicines for serious or life-threatening diseases. The decision is based on preliminary clinical evidence showing the investigational therapy may improve at least one clinically relevant outcome significantly, compared with available therapies.
Blocking HIF2 protein may promote lung repair in IPF: Mouse study
2025年1月10日 · Strides made in IPF research, but key questions remain. As with other forms of pulmonary fibrosis, IPF is characterized by progressively worsening inflammation and scarring, or fibrosis, in the lung epithelium — the protective cellular layer of the airways.Ultimately, alveoli, which are the tiny sacs responsible for gas exchange in the lungs, become damaged, leading to lung function decline ...
Top 10 Pulmonary Fibrosis Stories of 2021
2022年1月3日 · Using a computer-based, artificial intelligence approach, Aria Pharmaceuticals identified two new therapeutic candidates for IPF that showed promising efficacy in a mouse model of the disease. The two compounds, TXR-1002 and TXR-1007, showed in August that they have good tolerability and can reduce lung scarring (fibrosis) and inflammatory cells to a degree at least comparable to that seen ...
Nerandomilast Phase 3 clinical trial meets its primary goal in IPF
2024年9月27日 · FIBRONEER-IPF (NCT05321069) enrolled 1,177 patients, ages 40 and older, at several sites in the U.S., Canada, South America, Europe, Asia, and Australia. Full efficacy and safety data will be presented in the first half of 2025. The company intends to seek the nerandomilast’s approval for IPF to the U.S. Food and Drug Administration (FDA) and other regulatory agencies worldwide.
Study: ENV-101 improves IPF lung function, reverses fibrosis
2024年6月7日 · The trial also assessed the effects of treatment on key measures of lung fibrosis as assessed by high-resolution computed tomography (HRCT). Results showed treatment with ENV-101 significantly decreased the absolute percent of quantitative interstitial lung disease — which measures the extent of lung fibrosis — by 9.4%, compared with a …
What Is Pulmonary Fibrosis?
Pulmonary fibrosis (PF), as its name suggests, is a disease marked by scarring — or fibrosis — of the lungs, leading to shortness of breath. PF is part of a larger group of more than 200 lung conditions collectively known as interstitial lung diseases (ILDs), many of which are known to cause progressive fibrosis.. Types and causes of PF. In …